nach oben

Die Ophthalmologie

Erschienen in:

07.11.2019 | Systemischer Lupus erythematodes | Kasuistiken

Progressive Makulopathie trotz Absetzen der Chloroquin-Therapie – Multimodale Bildgebung und Review der Literatur

verfasst von: Dr. med. A. Rickmann, S. Al-Nawaiseh, L. Ramirez, S. Röhrig, M. Ladewig, P. Szurman, G. Szurman

Erschienen in: Die Ophthalmologie | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Dieser Bericht stellt einen multimodalen Fall mit Fortschreiten der Makulopathie trotz Abbruch der Chloroquin-Therapie im Langzeitverlauf von 6 Jahren dar. Darüber hinaus werden die aktuellen Nachweisverfahren im Screening zur Früherkennung der Makulopathie und ihre prognostische Bedeutung diskutiert.

Wei LC, Chen SN, Ho CL, Kuo YH, Ho JD (2001) Progression of hydroxychloroquine retinopathy after discontinuation of therapy: case report. Chang Gung Med J 24(5):329–334PubMed

Moschos M, Nitoda E, Chatziralli IP, Gatzioufas Z, Koutsandrea C, Kitsos G (2015) Assessment of hydroxychloroquine maculopathy after cessation of treatment: an optical coherence tomography and multifocal electroretinography study. Drug Des Devel Ther 9:2993PubMedPubMedCentral

Mititelu M, Wong BJ, Brenner M, Bryar PJ, Jampol LM, Fawzi AA (2013) Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging. JAMA Ophthalmol 131(9):1187–1197PubMed

Fava A, Petri M (2019) Systemic lupus erythematosus: diagnosis and clinical management. J Autoimmun 96:1–13PubMed

Kuhn A, Bonsmann G, Anders HJ, Herzer P, Tenbrock K, Schneider M (2015) The diagnosis and treatment of systemic lupus erythematosus. Dtsch Arztebl Int 112:423–432PubMedPubMedCentral

Fischer-Betz R, Schneider M (2009) Antimalariamittel. Therapieoption für jeden Lupus-Patienten?! Z Rheumatol 68:6–90

Jewell ML, McCauliffe DP (2000) Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 42(6):983–987PubMed

Mok SM, Tse KL, Chan LY, Ho LY (2018) Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort. Lupus 27(5):722–727PubMed

Ruberto G, Bruttini C, Tinelli C, Cavagna L, Bianchi A, Milano G (2018) Early morpho-functional changes in patients treated with hydroxychloroquine: a prospective cohort study. Graefes Arch Clin Exp Ophthalmol 256(11):2201–2210PubMed

10.

Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, Mavrikakis M (2003) The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology 110:1321–1326PubMed

11.

Melles RB, Marmor MF (2014) The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 132:1453–1460PubMed

12.

Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 123:1386–1394PubMed

13.

Korthagen NM, Bastiaans J, van Meurs JC, van Bilsen K, van Hagen PM, Dik WA (2015) Chloroquine and hydroxychloroquine increase retinal pigment epithelial layer permeability. J Biochem Mol Toxicol 29:299–304PubMed

14.

Lyons JS, Severns ML (2009) Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a review. Doc Ophthalmol 118:29–36PubMed

15.

Levy GD, Munz SJ, Paschal J, Cohen HB, Pince KJ, Peterson T (1997) Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum 40:1482–1486PubMed

16.

Johnson MW, Vine AK (1987) Hydroxychloroquine therapy in massive total doses without retinal toxicity. Am J Ophthalmol 104(139):44

17.

Bienfang D, Coblyn JS, Liang MH, Corzillius M (2000) Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation: a consecutive series. J Rheumatol 27:2703PubMed

18.

Rüther K, Foerster J, Berndt S, Schroeter J (2007) Variabilität der retinotoxischen Gesamtdosis Chloroquin/Hydroxychloroquin. Ophthalmologe 104(10):875–879PubMed

19.

Shroyer NF, Lewis RA, Lupski JR (2001) Analysis of the ABCR (ABCA4) gene in 4‑aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to stargardt disease? Am J Ophthalmol 131:761–766PubMed

20.

Gaynes BI, Torczynski E, Varro Z, Grostern R, Perlman J (2008) Retinal toxicity of chloroquine hydrochloride administered by intraperitoneal injection. J Appl Toxicol 28(7):895–900PubMed

21.

Chen TY, Lien WC, Cheng HL, Kuan TS, Sheu SY, Wang CY (2019) Chloroquine inhibits human retina pigmented epithelial cell growth and microtubule nucleation by downregulating p150glued. J Cell Physiol 234(7):10445–10457. https://doi.org/10.1002/jcp.27712PubMedCrossRef

22.

Wolfe F, Marmor MF (2010) Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res 62:775–784

23.

de Sisternes L, Hu J, Rubin DL, Marmor MF (2015) Localization of damage in progressive hydroxychloroquine retinopathy on and off the drug: inner versus outer retina, parafovea versus peripheral fovea. Invest Ophthalmol Vis Sci 56:3415–3426PubMedPubMedCentral

24.

Salu P, Uvijls A, van den Brande P, Leroy BP (2010) Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with 19 years follow-up. Doc Ophthalmol 120(3):251–264PubMed

25.

Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF, American Academy of Ophthalmology (2011) Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 118(2):415–422PubMed

26.

Michaelides M, Stover NB, Francis PJ, Weleber RG (2011) Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Arch Ophthalmol 129(1):30–39PubMed

27.

Chen E, Brown DM, Benz MS, Fish RH, Wong TP, Kim RY, Major JC (2010) Domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the “flying saucer” sign). Clin Ophthalmol 4:1151–1158PubMedPubMedCentral

28.

Brinkley TR, Dubois EL (1979) Long term course of chloroquine retinopathy after cessation of medication. Am J Ophthalmol 88:1–11PubMed

29.

Yusuf IH, Sharma S, Luqmani R, Downes SM (2017) Hydroxychloroquine retinopathy. Eye 31:828–845PubMedPubMedCentral

30.

Giocanti-Aurégan A, Couturier A, Girmens JF, Le Mer Y, Massamba N, Barreau E, Audo I (2018) DHU Vision Handicaps task force rétine. J Fr Ophtalmol 41(4):363–367PubMed

31.

Ahn SJ, Joung J, Lim HW, Lee BR (2017) Optical coherence tomography protocols for screening of hydroxychloroquine retinopathy in Asian patients. Am J Ophthalmol 184:11–18PubMed

32.

Kellner U, Renner AB, Tillack H (2006) Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine. Invest Ophthalmol Vis Sci 47:3531–3538PubMed

33.

Bulut M, Erol MK, Toslak D et al (2018) A new objective parameter in hydroxychloroquine-induced retinal toxicity screening test: macular retinal ganglion cell-inner plexiform layer thickness. Arch Rheumatol 33(1):52–58PubMed

34.

Cabral RTS, Klumb EM, Couto MINN, Carneiro S (2019) Evaluation of toxic retinopathy caused by antimalarial medications with spectral domain optical coherence tomography. Arq Bras Oftalmol 82(1):12–17PubMed

35.

Bulut M, Akıdan M, Gözkaya O, Erol MK, Cengiz A, Çay HF (2018) Optical coherence tomography angiography for screening of hydroxychloroquine-induced retinal alterations. Graefes Arch Clin Exp Ophthalmol 256(11):2075–2081PubMed

36.

Bae EJ, Kim KR, Tsang SH, Park SP, Chang S (2014) Retinal damage in chloroquine maculopathy, revealed by high resolution imaging: a case report utilizing adaptive scanning laser ophthalmoscopy. Korean J Ophthalmol 28(1):100–107PubMedPubMedCentral

37.

Debellemanière G, Flores M, Tumahai P, Meillat M, Bidaut Garnier M, Delbosc B, Saleh M (2015) Assessment of parafoveal cone density in patients taking hydroxychloroquine in the absence of clinically documented retinal toxicity. Acta Ophthalmol 93(7):e534–40PubMed

38.

Turgut B, Turkcuoglu P, Serdar Koca S, Aydemir O (2009) Detection of the regression on hydroxychloroquine retinopathy in optical coherence tomography. Clin Rheumatol 28:607–609PubMed

39.

Tsang AC, Ahmadi Pirshahid S, Virgili G, Gottlieb CC, Hamilton J, Coupland SG (2015) Hydroxychloroquine and chloroquine retinopathy: a systematic review evaluating the multifocal electroretinogram as a screening test. Ophthalmology 122:1239–1251.e4PubMed

40.

Hood DC, Frishman LJ, Saszik S, Viswanathan S (2002) Retinal origins of the primate multifocal ERG: implications for the human response. Invest Ophthalmol Vis Sci 43:1673–1685PubMed

41.

Arndt C, Costantini M, Chiquet C, Afriat M, Berthemy S, Vasseur V, Ducasse A, Mauget-Faÿsse M (2018) Comparison between multifocal ERG and C‑Scan SD-OCT (“en face” OCT) in patients with a suspicion of antimalarial retinal toxicity: preliminary results. Doc Ophthalmol 136(2):97–111PubMed

42.

Easterbook M (1992) Long term courses of antimalarial maculopathy after cessation of treatment. Can J Ophthalmol 27:237–239

43.

Vavvas D, Huynh N, Pasquale L, Berson EL (2010) Progressive hydroxychloroquine toxicity mimicking low-tension glaucoma after discontinuation of the drug. Acta Ophthalmol 88(1):156–157PubMed

44.

Fung AE, Samy CN, Rosenfeld PJ (2007) Optical coherence tomography findings in hydroxychloroquine and chloroquine-associated maculopathy. Retin Cases Brief Rep 1(3):128–130PubMed

45.

Marmor MF (2012) Comparison of screening procedures in hydroxychloroquine toxicity. Arch Ophthalmol 130:461–469PubMed

46.

Paulose RM, Chhablani J, Jhingan M (2017) Update on hydroxychloroquine retinopathy. Kerala. J Ophthalmol 29:9–13

Titel: Progressive Makulopathie trotz Absetzen der Chloroquin-Therapie – Multimodale Bildgebung und Review der Literatur
verfasst von: Dr. med. A. Rickmann
S. Al-Nawaiseh
L. Ramirez
S. Röhrig
M. Ladewig
P. Szurman
G. Szurman
Publikationsdatum: 07.11.2019
Verlag: Springer Medizin
Schlagwörter: Systemischer Lupus erythematodes
Chloroquin
Chloroquin
Hydroxychloroquin
Erschienen in: Die Ophthalmologie / Ausgabe 9/2020
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI: https://doi.org/10.1007/s00347-019-00994-6

Neu im Fachgebiet Augenheilkunde

08.04.2024 | Therapieverfahren in der Augenheilkunde | CME

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Progressive Makulopathie trotz Absetzen der Chloroquin-Therapie – Multimodale Bildgebung und Review der Literatur

Zusammenfassung

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

Bestmögliche Wundheilung der Kornea dank optimaler pharmakologischer Therapie

Update Augenheilkunde

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2020

Zum Status der Personalplanung für den ärztlichen Dienst in ophthalmologischen Hauptabteilungen in Deutschland

Glaskörperblutung – Wie lange kann man abwarten?

Partielle Retinafensterung bei Grubenpapillenmakulopathie

Rotes Auge einmal anders

Hornhautveränderungen bei Liderkrankungen

Therapie subretinaler Makulablutungen

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

Bestmögliche Wundheilung der Kornea dank optimaler pharmakologischer Therapie

Update Augenheilkunde